Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ...
Scientists have discovered a new mechanism by which cancerous cells in acute myeloid leukemia (AML) regulate the protein IDH2 (isocitrate dehydrogenase2) known to be mutated in cancer, to increase the ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has ...
Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a new study. Researchers revealed new insights into how acute myeloid leukemia (AML) ...
Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback